A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled αvβ6 integrin inhibitor
(2020)
Journal Article
Maher, T. M., Simpson, J. K., Porter, J. C., Wilson, F. J., Chan, R., Eames, R., Cui, Y., Siederer, S., Parry, S., Kenny, J., Slack, R. J., Sahota, J., Paul, L., Saunders, P., Molyneaux, P. L., Lukey, P. T., Rizzo, G., Searle, G. E., Marshall, R. P., Saleem, A., …Vahdati-Bolouri, M. (2020). A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled αvβ6 integrin inhibitor. Respiratory Research, 21(1), Article 75. https://doi.org/10.1186/s12931-020-01339-7
© 2020 The Author(s). Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease with poor prognosis and a significant unmet medical need. This study evaluated the safety, pharmacokinetics (PK) and target engagement in the... Read More about A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled αvβ6 integrin inhibitor.